CompletedPhase 4

Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

United States813 participantsStarted 2022-10-18

Plain-language summary

This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕Target Disease Exclusion:
✕. History of cluster headache, basilar migraine, or hemiplegic migraine
✕. Current medication overuse headaches
✕. Headaches occurring 15 or more days per month (migraine or non-migraine) in any of the 3 months prior to the Screening Visit
✕. Active chronic pain syndrome (such as fibromyalgia, chronic pelvic pain, complex regional pain syndrome \[CRPS\])
✕. Other pain syndromes (including trigeminal neuralgia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, interfere with study assessments of safety or efficacy

What they're measuring

Percentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT Phase

Timeframe: At 2 hours post-dose

Trial details

NCT IDNCT05509400

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-03-10

Results submitted2026-03-06

View on ClinicalTrials.gov More Migraine trials